New Haven Needle Exchange Program Was it effective in reducing HIV transmission? Was it cost-effective?

Slides:



Advertisements
Similar presentations
North Carolina Harm Reduction Coalition. North Carolina Harm Reduction Coalition (NCHRC) is North Carolina’s only comprehensive harm reduction program.
Advertisements

Bringing Opioid Substitution Treatment to scale Dr. M. Suresh Kumar Inter-country Consultation on Preventing HIV among IDUs Scaling Up: From Evidence to.
CASE STUDIES OF PUBLIC HEALTH RESEARCH THAT HAVE ALTERED PUBLIC POLICY THE NEW HAVEN SEP EVALUATION.
Operations Research2  The problem  With the advent of HIV and AIDS in the early 1990s, the City of New Haven instituted a needle exchange program as.
Models of Harm Reduction
The hidden HIV epidemic: what do mathematical models tell us? The case of France Virginie Supervie, Jacques Ndawinz & Dominique Costagliola U943 Inserm.
HIV Risk Behaviors and Alcohol Intoxication among Injection Drug Users in Puerto Rico Tomás D. Matos, MS Center for Addiction Studies Universidad Central.
HIV/AIDS AMONG LATINOS IN NEW JERSEY presented by: Gloria M. Rodriguez, DSW Assistant Commissioner Division of AIDS Prevention and Control presented at.
Cost-Effectiveness of Needle Exchange Program among IDUs in Uzbekistan Azizbek A. Boltaev IREX Contemporary Issues Program Fellow Dynamic Communications:
Hepatitis C Awareness and Risky Injection Behaviors among Injection Drug Users in Treatment PT Korthuis 1, D Feaster 2, Z Gomez 2, M Das-Douglas 3, S Tross.
Drug Abuse TreatmentPage 1 of 32 Cost Effectiveness of Maintenance Treatment for Heroin Addicts Professor Margaret Brandeau Department of Management Science.
HIV and Hepatitis C in non- MSM Rural Communities: Issues and Interventions Shari Wells-Weiss, CASAC Director of Prevention Services Southern Tier AIDS.
The HIV/AIDS Epidemic © 2005 John B. Pryor Illinois State University.
Slide 5.1 Topic 5. Supporting programs aimed at reducing the spread of HIV among and from IDU Needle and Syringe Programs Opioid Substitution Treatment.
Drug policy and harm reduction: impact of the US policy Raminta Stuikyte Central and Eastern European Harm Reduction Network.
Overview of Syringe Exchange Programs New York City Police Academy November 24, 2004.
Incorporating HIV and Viral Hepatitis Testing and Referral into Idaho Drug Court Programs Presented by Idaho Advisory Council on HIV and AIDS, Bebe Thompson,
Afghanistan’s Present IDUs-HIV/AIDS Situation and future action plan Dr.Saifur-Rehman NACP Director April,11,2007 Islamic Republic of Afghanistan Ministry.
Background Donor Suitability Consultation was held in Atlanta June 26-27, 2001 To review and consult on the 1994 CDC Guidelines for Preventing Transmission.
 Insufficient Reliable data in this region  Estimated people living with HIV  The number of new HIV infections in the region increased.
HIV/AIDS Chapter 21 Human Immunodeficiency Virus (HIV) Acquired immune Deficiency Syndrome (AIDS) (Pg 496)
Don’t get spun! How to spot data torturing, and other tricks of the trade Elizabeth Pisani Vienna, 2010.
Chapter 1: An Overview of the HIV/AIDS Epidemic Module 1, Chapter 1.
Expanded and Enhanced Treatment Services in a Los Angeles OTP Funded by The Center for Substance Abuse Treatment Targeted Capacity Expansion for Substance.
Concepts in Infectious Disease Epidemiology: Models & Prediction David Vlahov, Ph. D.
Centers for Disease Control and Prevention CDC Half-Year of Diagnosis** Number of Cases **Adjusted for reporting delay AIDS Cases in Racial/Ethnic Minorities*
New Haven-Fairfield Counties End of Year Studies: Ryan White Planning Council New Haven-Fairfield Counties End of Year Studies: Ryan White Planning Council.
Harm Reduction.
Overview of Harm Reduction and Sterile Syringe Access Anna Benyo Syringe Access Policy Coordinator Harm Reduction Coalition New Jersey Syringe Access Informational.
COUNTRY PRESENTATION (DRUGS AND HIV/AIDS)– Nepal Dr. Krishna Kumar Rai, Director National Centre for AIDS and STD Control, Ministry of Health and Population.
Preventing Medical Complications of Injection Drug Use Keith Heinzerling, MD, MPH UCLA Seminars in Addiction Psychiatry Course August 11, 2005.
TI for IDUs Sexual IDUBlood Perinatal Unidentified Routes of HIV Transmission SENTINEL SURVEILLANCE 2006 HIV infection in India.
To Increase Investment in Syringe Exchange in the U.S. would be Cost-saving. Results from modeling hypothetical syringe coverage levels INTL AIDS CONF.
HIV and AIDS Data Hub for Asia-Pacific HIV and AIDS Data Hub for Asia-Pacific Review in slides China 1.
Drug Use and Hepatitis C Are we mindful of the gaps? Dave Liddell, SDF.
A global perspective on scaling up harm reduction 2 nd National Harm Reduction Conference, Ukraine, March 2007 Dr Jos Perriens, Director Prevention.
Epidemiological Impact and Cost Effectiveness of Harm Reduction Programmes in Russia Based on the results of the Global Fund Round 5 HIV Programme in Russia,
Introduction About HIV/AIDS in Hangzhou Hangzhou Center For Disease Control And Prevention — by Zhao Gang — by Zhao Gang.
2008 Minnesota HIV/AIDS Surveillance Report - Key Trends Lorraine Teel- Executive Director.
The Minority AIDS Initiative (MAI): Then and Now Edwin M. Craft, Dr. P
Data Trends: FPAR & HIV Prevention Project OPA/OFP HIV Prevention Project Annual Technical Support Conference June 12, 2007 Presented by Kelly Morrison.
World Bank Seminar Series: Global Issues Facing Humanity Diseases without borders.
Lifting the Federal Ban on the funding of syringe exchange: An advocacy campaign Allan Clear XVIII International AIDS Conference.
SSuN: MSM prevalence monitoring and HIV Testing in STD Clinics Kristen Mahle & Lori Newman SSuN Call #3 Oct 30, 2008.
National roll-out of database for HIV prevention programmes among civil society organizations in Ukraine Olga Varetska ICF “International HIV/AIDS Alliance.
Paradoxes and Problems in Preventing HIV Infection among Injecting Drug Users and Their Sexual Partners in Eastern Europe and Asia Don C. Des Jarlais,
Kow-Tong Chen, M.D., Ph.D., Hsiao-Ling Chang, Ph.D., Chu-Tzu Chen, M.P.H., and Ying-An Chen, M.P.H. Volume 23, Number 3, 2009 AIDS PATIENT CARE and STDs.
PLACE Method Priorities for Local AIDS Control Efforts 1 1 MEASURE Evaluation, A Manual for implementing the PLACE Method.
1 Where have we failed? Findings of the Commission on AIDS in Asia Tim Brown East-West Center Modes of Transmission in the Philippines Stakeholders’ meeting.
Substance Abuse Treatment and HIV in Iran
Hepatitis C: The Silent Epidemic Wednesday, October 21, 2015 John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention.
HIV Testing Strategies and Linkage to Care for Criminal Justice Populations Timothy P. Flanigan, MD Professor of Medicine Brown Medical School.
Delivery Systems for Substance Abuse Treatment in MAURITIUS. DR. FAYZAL SULLIMAN COORDINATOR MEDICAL & RESEARCH UNIT NATReSA.
Jennifer R. Havens, PhD, MPH Associate Professor
HIV/AIDS in Eastern Europe Setting the Stage for Prevention HIV/AIDS in Eastern Europe Setting the Stage for Prevention Thomas E. Novotny, MD, MPH April.
Can Difficult-to-Reuse Syringes Reduce the Spread of HIV Among Injection Drug Users? -Caulkins, Kaplan, Lurie, O’Connor & Ahn Presented by: Arifa Sultana.
HIV in India David S. Hausner American Embassy School 8 th Grade Population Project 24 February 2012.
Trends in the Prevalence of Hepatitis C and Hepatitis B and HIV in Seattle Injection Drug Users, 18 – 30 years old, Richard Burt, Holly Hagan,
High Coverage of Most-at-Risk Populations Reduces HIV Risk: Results from Central Asia Anna Deryabina, David S. Hausner, Bibigul Aubakirova, Yana Dobronravova,
HIV Prevention: A Winnable Battle Centers for Disease Control and Prevention.
Current state of HIV and associated infections epidemic among adolescents and youth: LATVIA Anda Karnite, MPH, PHD Riga Stradins University and Baltic.
Harm reduction evidence: Eastern Europe and Central Asia Raminta Stuikyte Central and Eastern European Harm Reduction Network.
First originated in Africa as two strands (HIV1 and HIV2) Infects cells of the immune system and destroys their function In the early 1980s HIV/AIDS were.
Thematic Priorities for ATF Applications Presentation by Secretariat of Council for the AIDS Trust Fund in Briefing Session on 27 July
Quick Review This presentation is the first in a series of presentations intended to familiarize you with disparities calculation Part I: YOU ARE HERE!
Needle and syringe exchange and working with injecting drug users
Sherry Deren, Sung-Yeon Kang, Milton Mino & Honoria Guarino
Edward Mbizo Sibanda, (MSc) Right to Care
Mission: To reduce morbidity associated with the prevalence of TB and HIV among at-risk drug users and their contacts.
Human Dignity and Harm Reduction
Presentation transcript:

New Haven Needle Exchange Program Was it effective in reducing HIV transmission? Was it cost-effective?

US History of HIV 1981 CDC MMWR reports unusual pneumonia in 5 gay men in LA 1982 CDC coins the name AIDS 1983 HIV virus discovered 1985 HIV test approved 1986 AZT approved 1987 US bans HIV+ immigrants and visitors 1991 More drugs approved 1997 Combination therapy becomes standard

Drug use and the spread of HIV IDU = injection drug user 1/3 of US AIDS cases can be traced to drug injection 1/2 of new HIV infections can be traced to drug injection Spread of HIV among IDUs in NYC –1985: prevalence close to 0 –1988: 40% of IDUs infected Becomes clear by 1987 that IDUs are dominant mode of transmission in New Haven Reducing spread among IDUs a priority!

Reducing spread of HIV among IDUs Drug abuse treatment (e.g., detox, rapid detaox, residential programs) Maintenance treatment (e.g., methadone, buprenorphine) Bleach/education programs Needle exchange programs

Politics around needle exchange Proponents: –Reduce HIV spread –Doesn’t increase drug use –Helps vulnerable minority populations Opponents: –No evidence they reduce HIV spread –Encourages drug use –Admits defeat in war on drugs

History of Needle Exchange 1984 Implemented in Amsterdam 1988 First US program in Tacoma, Washington 1988 Use of federal funds is banned 1990 May Connecticut legislature allows New Haven needle sharing program Nov. Program starts 1991 March initial data reported 1992 Syringe possession decriminalized in Connecticut 1993 Paper wins Edelman Award 1998 Dept of HHS report “NEPs: Part of a Comprehensive HIV Prevention Strategy” Currently ~200 needle exchange programs in US

Early needle exchange studies Relied on self-reported behavior about reduction in risky behavior Did not incorporate quantity of needles exchanged

New Haven program Used needles exchanged 1-1 (up to 5) for new ones Program clients and needles had IDs Date, location, client ID, and needle IDs recorded at distribution and return of needles Samples of needles tested for HIV

Initial data from random testing % HIV infected 91.5% (44/48) needles from “shooting gallery” 67.5% (108/160) street needles at program start 50.3% (291/579) program needles (first 15mo) 40.5% (147/367) program needles (next 12mo) But how does reduced needle prevalence translate into reduced HIV transmission?

Circulation Approach Needle exchange… –Keeps number of needles in circulation constant –Increases needle turnover, thus reducing the time a needle is in circulation Shorter circulation time reduces the number of uses (and users) per needle Thus, decrease in number of infected needles

Notation and Parameter Estimates = 0.674shared drug injections / client / year  = 0.84probability a needle is bleached before injection  = 0.1removal rate / HIV-infected client / year  = Pr [ HIV transmission probability | infected needle]  = 20.5 needle exchanges / circulating needle / year  = # clients / #circulating needles  (t) fraction of circulating needles infected with HIV  (0)=0.675  (t)HIV prevalence among program clients  (0)=0.636 C( T )new infections over time period T / IDU

Model  ´(t) = [1-  (t)] (1-  )  (t)  -  (t)   ´(t) = [1-  (t)]   (t) -  (t)[  +  (1-  (t))] C( T ) =  t=0..T  [1-  (t)] (1-  )  (t)  dt HIV spread: IDU -> needle -> IDU Malaria spread: humans -> mosquitoes -> humans Needle exchange and bleach ~ replacing infected mosquitoes with uninfected ones

Effectiveness One year horizon No needle exchange (  =0) –C(1)=0.064 = 6.4 HIV infections / 100 IDUs / year With needle exchange (  =20.5) –C(1)=0.043 = 4.3 HIV infections / 100 IDUs / year Incidence reduced by 33%.

Other Outcomes No evidence of increase in drug injection 1/6 of IDUs in program enter treatment Program attracts minority clients –Local drug treatment: 60% white –Program clients: 60% nonwhite.

Cost Effectiveness Program cost: ~ $150,000 / year Lifetime hospital costs / infection ~ $50k-100k 20 infections averted Cost saving!

Sensitivity Assume  (t) constant Approximately,  I decreases as – increases –  decreases –  decreases Results robust  I =  (0)  +  (0)+1-  (0)]

Estimating rate of shared injections Self-reported 2.14 injections / client / day Sharing rate –Self-reported 8.4% –But 31.5% of program needles returned by different client than originally issued to –Assume 31.5% (conservative) Thus, 

Estimating probability of bleaching  Bleach outreach program begun in 1987 Self-reported 84% use of bleach Thus,  =0.84

Estimating IDU departure rate  Departures due to –Development of AIDS –Drug treatment (1/6 of clients) –Hospitalization, jail, relocation,… Assume departures due only to AIDS (conservative) Mean time to AIDS ~ 10 years Thus, 

Estimating initial conditions  (0),  (0) From needle data (108 infected / 160 tested) –Thus,  Other studies on HIV prevalence among IDUs,  –13% seeking treatment –36% at STD clinics –67% of African American men entering treatment Assume at equilibrium before program starts: –  ´(0)=0,  ´(0)=0,  =0 –Thus,  (0)=  (1-  )  ] = 0.636

Estimating infectivity per injection  Studies of accidental needle sticks –Chance of transmission ~ Drug injection has higher probability Assume at equilibrium before program start: –  ´(0)=0,  ´(0)=0,  =0 –  Thus,  =  (1-  )(1-  = 0.066

Estimating the needle exchange rate  Random variable T r = time until needle returned –Exponential dist with rate  –  = needle exchanges / needle / year Random variable T l = time until needle is lost –Exponential dist. with rate  –  = rate at which needles lost / year Random variable L = 1 if needle is legible, else 0 –Bernoulli with probability l –l=0.86 fraction of needles whose code is legible

Estimating the needle exchange rate  x i = 1 if the i th needle has been returned, else 0 t i = observed (censored) circulation time of i th needle If x i =1, then t i =T r <T l and L=1 –Likelihood =  exp[-(  )t i ] · l If x i =0, then T l <T r Likelihood:  /(  ) or (T r <T l and L=0)Likelihood:  /(  ) · (1-l) or (t i <min{T r,T l } and T r <T l and L=1) Likelihood:  /(  ) · exp[-(  )t i ] · l

Estimating the needle exchange rate  max  log L = ∑ i I(x i =1) log [  exp[-(  )t i ]l] + I(x i =0)log[  /(  (1-l)  /(  ) + l[  /(  )]exp[-(  )t i ]] Max likelihood estimates –  = 20.5 needle exchanges / needle / year –  = 23.1 lost needles / circulating needle / year

Estimating #clients / #needles   = D/N N = number of needles in circulation D = number of IDUs in the program Assume number of needles constant, N  = D  = 20.5 needle exchanges / needle / year = needles distributed / IDU / year Thus,  20.5/122.4=0.1675